Friday, April 19, 2024
News

Explained: India''s first mRNA Covid vax

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

New Delhi | Tuesday, 2022 1:45:07 AM IST
India is soon set to begin human trials on its first home-grown Covid vaccine based on Messenger RNA (mRNA) technology.

Pune-based Gennova Biopharmaceuticals is making India''s first mRNA vaccine known as HGC019, in collaboration with US-based HDT Bio Corp.

In August, the Drug Controller General of India had approved the Phase 2 and 3 clinical trials.

"The Vaccine Subject Expert Committee (SEC) reviewed the data, and found HGCO19 to be safe, tolerable, and immunogenic in the participants of the study," the company had said in a statement.

The company will start testing the vaccine on humans for efficacy and immunogenicity from next month. The mRNA vaccine is also reportedly effective against the newA Omicron variant.

The mRNA vaccines carry the molecular information to make the protein in the host using the synthetic RNA of the virus. The host body produces the viral protein that is recognised by the immune system, thereby enabling the body to fight against the disease.

mRNA vaccines are considered safe as mRNA is non-infectious, non-integrating in nature, and degraded by standard cellular mechanisms. They are highly efficacious because of their inherent capability of being translated into proteins in the cell.

These vaccines also represent a promising alternative to conventional vaccine approaches because of their high potency, capacity for rapid development, and potential for low-cost manufacture and safe administration.

Researchers have been studying and working with mRNA vaccines for decades. It can be developed in a laboratory using readily available materials, meaning the manufacturing can be faster.

mRNA vaccines have elicited potent immunity against infectious disease targets in animal models of influenza virus, Zika virus, rabies virus and others, especially in recent years.

It has also been employed in numerous cancer clinical trials, with some promising results showing antigen-specific T cell responses and prolonged disease-free survival in some cases.

Future mRNA vaccine technology may allow for one vaccine to provide protection against multiple diseases, thus decreasing the number of shots needed for protection against common vaccine-preventable diseases.

--IANS rvt/vd

( 345 Words)

2022-01-17-19:40:04 (IANS)

 
  LATEST COMMENTS ()
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE HEALTH NEWS
Do you know immunotherapy post-surgery i...
Researchers discover new metric for diag...
Study gives more insight into molecular ...
Researchers reveal impact of aldehydes o...
Gut bacteria can influence obesity in me...
Alcohol usage during pregnancy linked to...
More...
 
INDIA WORLD ASIA
Delhi: AAP MLA Amanatullah Khan question...
Voting begins in 102 seats in first phas...
Vice Admiral Dinesh Tripathi appointed a...
Delhi LG seeks report from DG Prisons ov...
Arunachal elections 2024: State ready fo...
Maharashtra LS polls: Supriya Sule owes ...
More...    
 
 Top Stories
Lok Sabha polls: PM Modi urges peop... 
LS polls: Former Tamil Nadu CM Edap... 
Congress leader P Chidambaram casts... 
Lok Sabha polls: RSS Chief Mohan Bh... 
Lok Sabha elections 2024: Manipur v... 
At UN, Iran warns of 'decisive resp... 
World Bank asks Pakistan govt to ma... 
Everyone's nerves got tested: Hardi...